AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$HIMS

Okupe Oluyemi sold $148K of HIMS

Okupe Oluyemi (Chief Financial Officer) sold 4,938 shares of Hims & Hers Health, Inc. (HIMS) at $29.99 ($0.15M total) on 2026-08-19 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Okupe Oluyemi
Published Aug 20, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HIMS
Neutral
medium confidence
Mentioned
$HIMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

The disclosed sale provides a data point for monitoring insider activity but lacks material impact.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming earnings or guidance that may change the perception of the sale.

Relevance 3/10Novelty 4/10Timing: post-market 2026-08-19

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$HIMSNeutralMedium confidence
Context

CFO Okupe Oluyemi sold 4,938 shares of Hims & Hers Health for $148,111 via a 10b5-1 plan.

Expected impact

Minimal short-term impact; price likely unchanged.

Evidence & confidence

Sale size (~$148k) is small compared to total holdings (264,117 shares) and typical market volume.

Market effects

Sector

None significant for the broader health‑tech sector.

Regional

Limited to U.S. investors tracking HIMS.

Global

Low

Counterpoint

What could challenge this read

If the CFO is offloading shares ahead of undisclosed negative news, the sale could foreshadow downside.

Key entities

  • Person
    Okupe Oluyemi

    Chief Financial Officer of Hims & Hers Health

  • Company
    Hims & Hers Health, Inc.

    U.S. telehealth and wellness company

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

OCT 28
$HIMSHighAI 8/10

Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding

Hims & Hers Health (HIMS) shares rose 6% after HHS announced enforcement discretion for six peptides, potentially benefiting Hims' peptide facility. The company awaits final FDA rules for a full launch. Hims' gross margin fell to 63.8% in Q2, with Q3 results on Nov. 9. Analysts estimate the peptide market at $2.2B-$3.3B, and Hims' revenue at $4.49B by 2028.

finance.yahoo.com2 min
OCT 26
$HIMSMed

Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions

Hims & Hers Health Inc. asked a California judge to dismiss an FTC lawsuit alleging deceptive practices, improper data sharing, and difficult subscription cancellations. The company claims its privacy policy is clear and the FTC misapplied federal law. The FTC argues Hims violated a 2010 law requiring clear disclosure of subscription terms. Hims has 2.6 million subscribers. A hearing is scheduled for January 7.

claimsjournal.com2 min